Danaher (DHR) Q1 2026 (USD): Adj. EPS 2.06 (exp. 1.94), Revenue 6bln (exp. 5.99bln); FY Outlook Adj. EPS 8.35-8.55 (exp. 8.40, prev. guided 8.35-8.50)

Danaher reported stronger-than-expected Q1 2026 results, with adjusted EPS and revenue both surpassing estimates, which reflects robust demand and effective cost management. The FY outlook adjustment is slightly above prior guidance, suggesting confidence in continued growth but not a dramatic shift. This may positively influence sentiment around the life sciences sector and indicate potential upward revisions across peers.